Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Clézardin

Showing results (1-10 of 86) with videos related to

Pageof 9
Sort By:
Seminars in Oncology|February 14, 2003
The antitumor potential of bisphosphonatesPhilippe Clézardin
Bulletin Du Cancer|October 25, 2013
[Pathophysiology of bone metastases and new molecular targets involved in bone remodelling]Philippe Clézardin
Bone|July 27, 2010
Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug classPhilippe Clézardin
Cancer Treatment Reviews|October 18, 2005
Anti-tumour activity of zoledronic acidPhilippe Clézardin
Bulletin Du Cancer|June 25, 2011
[The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications]Philippe Clézardin
Bonekey Reports|January 15, 2014
Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activitiesPhilippe Clézardin
Joint Bone Spine|May 14, 2017
Pathophysiology of bone metastases from solid malignanciesPhilippe Clézardin
Breast Cancer Research : BCR|May 19, 2011
Therapeutic targets for bone metastases in breast cancerPhilippe Clézardin
Cancer Treatment Reviews|October 11, 2011
Direct and indirect anticancer activity of bisphosphonates: a brief review of published literatureMichael Gnant, Philippe Clézardin
Seminars in Oncology|August 5, 2010
The molecular basis of bisphosphonate activity: a preclinical perspectiveJonathan Green, Philippe Clézardin
Pageof 9

Showing results (1-10 of 86) with videos related to

Sort By:
Pageof 9
Seminars in Oncology|February 14, 2003
The antitumor potential of bisphosphonatesPhilippe Clézardin
Bulletin Du Cancer|October 25, 2013
[Pathophysiology of bone metastases and new molecular targets involved in bone remodelling]Philippe Clézardin
Bone|July 27, 2010
Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug classPhilippe Clézardin
Cancer Treatment Reviews|October 18, 2005
Anti-tumour activity of zoledronic acidPhilippe Clézardin
Bulletin Du Cancer|June 25, 2011
[The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications]Philippe Clézardin
Bonekey Reports|January 15, 2014
Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activitiesPhilippe Clézardin
Joint Bone Spine|May 14, 2017
Pathophysiology of bone metastases from solid malignanciesPhilippe Clézardin
Breast Cancer Research : BCR|May 19, 2011
Therapeutic targets for bone metastases in breast cancerPhilippe Clézardin
Cancer Treatment Reviews|October 11, 2011
Direct and indirect anticancer activity of bisphosphonates: a brief review of published literatureMichael Gnant, Philippe Clézardin
Seminars in Oncology|August 5, 2010
The molecular basis of bisphosphonate activity: a preclinical perspectiveJonathan Green, Philippe Clézardin
Pageof 9